CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2018—The FDA has approved Senseonics Holdings’ Eversense Continuous Glucose Monitoring System for adults age 18 and older with diabetes. The system features an implantable glucose sensor and provides long-term continuous monitoring for up to three months.
Read More »